Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Renal Cell Carcinoma

Expert Opinion / Cases · November 03, 2014

Management Options for Collecting Duct Carcinoma

Written by
Manjari Pandey MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Manjari Pandey MD

    Manjari  Pandey MD

    Nov 04, 2014

    The patient was presented at our institution's tumor board and the consensus was to proceed with palliative chemotherapy with gemcitabine/ carboplatin. It was felt that there is no role for radiation therapy at this time.

    CT staging scans revealed clear chest except for granulomatous disease, multiple enlarged retroperitoneal aortocaval and paracaval lymph nodes as well as multiple bilobar metastatic lesions.

    She initiated palliative chemotherapy with gemcitabine and carboplatin and tolerated well with no significant cytopenias or other untoward side effects.

  • jerrold tomlin

    Nov 09, 2014

    Why no sunitinib.?

  • Brad Somer

    Nov 24, 2014

    Collecting duct carcinomas have a much more aggressive behavior than clear cell carcinoma.  They are typically more biologically similar to  transitional cell carcinoma of the renal pelvis. There are case reports of VEGF-TKIs but most experience is with chemotherapy and in a review on collecting duct tumors in Current Oncology, 20 (3), 2013, Dason et al there was 26% response rate with Gem+platinum agent.

  • dalila amokrane

    Dec 31, 2014

    we use gemcitabine +platinum agent but no response was observed in 5 patients 

  • Feb 22, 2024

    Pending Moderator approval.

Further Reading